Honors & Awards

  • Research Grant, Stanford MedScholars (2015-17)
  • Ouyang Fellowship, Amherst College (2012)

Membership Organizations

  • WAM: Women and Medicine, President (2016-17)
  • Pacific Free Clinic, Specialty Clinic Manager (2016-17, 2019-20)
  • Stanford Medical Student Association, Vice President (2016), Class Representative (2017)

Contact

  • Academic
    sarachoi@stanford.edu
    University - Student Department: Health Research and Policy - Epidemiology Position: Graduate
    University - Student Department: School of Medicine Position: Graduate, Medicine

Additional Info

  • Mail Code: 5404

Research Projects

  • A Phase 2 Trial of a Neurokinin-1 Receptor Agonist for the Treatment of Pruritus in Epidermolysis Bullosa (MedScholars Project)

All Publications

  • Phase 2 Trial of a Neurokinin-1 Receptor Antagonist for the Treatment of Chronic Itch in Epidermolysis Bullosa Patients: A Randomized Clinical Trial. Journal of the American Academy of Dermatology Chiou, A. S., Choi, S., Barriga, M., Dutt-Singkh, Y., Solis, D. C., Nazaroff, J., Bailey-Healy, I., Li, S., Shu, K., Joing, M., Kwon, P., Tang, J. Y. 2019

    Abstract

    BACKGROUND: Chronic pruritus causes major morbidity in epidermolysis bullosa (EB). The substance P-neurokinin 1 receptor (SP-NK1) pathway is a promising target for treating EB-related pruritus.OBJECTIVE: To evaluate the safety and efficacy of oral NK1 receptor antagonist serlopitant in treating moderate-severe pruritus in EB.METHODS: 14 patients were randomized to serlopitant or placebo for 8 weeks, followed by a 4-week washout and optional open-label extension. The primary endpoint was change in itch as measured by a numeric rating scale (NRS). Secondary endpoints were change in: (1) itch during dressing changes and (2) wound size.RESULTS: We observed greater itch reduction with serlopitant, equivalent to a 0.64-point comparative reduction on the 11-point NRS by week 8, though this failed to meet statistical significance (p=0.11). More serlopitant patients achieved ≥3-point reduction compared to placebo (43% vs. 14%, p=0.35). In post hoc analysis excluding one subject with a concurrent seborrheic dermatitis flare, serlopitant achieved significantly greater median itch reduction from baseline by week 4 (-2 points vs. 0, p=0.01). We observed no statistically significant differences in secondary endpoints. Serlopitant was well-tolerated.LIMITATIONS: Small sample size due to disease rarity CONCLUSION: The potential itch reduction with serlopitant observed in this trial will be pursued by a larger powered trial (NCT03836001).

    View details for DOI 10.1016/j.jaad.2019.09.014

    View details for PubMedID 31541747

  • Incidence and Risk of Severe Ileus After Orthopedic Surgery: A Case-Control Study HSS Journal Mandl, L. A., Sasaki, M., Yang, J., Choi, S., Cummings, K., Goodman, S. M. 2019

    View details for DOI 10.1007/s11420-019-09712-z

  • Cardiotoxicity associated with immune checkpoint inhibitors in cutaneous oncology. Journal of the American Academy of Dermatology Tabata, M. M., Choi, S., Hirotsu, K., Kwong, B., Soleymani, T. 2019

    View details for DOI 10.1016/j.jaad.2019.08.033

    View details for PubMedID 31437546

  • Dietary carotenoids and bacterial infection in wild and domestic convict cichlids (Amatitlania spp.) ENVIRONMENTAL BIOLOGY OF FISHES Brown, A. C., Cahn, M. D., Choi, S., Clotfelter, E. D. 2016; 99 (4): 439–49

    View details for DOI 10.1007/s10641-016-0485-x

    View details for Web of Science ID 000374670500010